Newly diagnosed multiple myeloma: How many drugs are enough?

Research output: Contribution to journalArticlepeer-review


The treatment of multiple myeloma (MM) has evolved over the past decade, yet it remains a chronic disease. Several trials of 4-drug induction regimens have resulted in deepening of disease response.With the emergence of multidrug regimens, questions have arisen regarding the role of autologous stem cell transplant (ASCT) in MM therapy and available treatment options after ASCT. Clinicians have also continued to improve the efficacy of maintenance therapies. In transplant-ineligible patients, the phases of treatment are less distinct; however, several regimens have demonstrated efficacy in this clinical setting. Future research should focus on individualizing treatment approaches.

Original languageEnglish (US)
Pages (from-to)1347-1350
Number of pages4
JournalJNCCN Journal of the National Comprehensive Cancer Network
StatePublished - Nov 2021

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Newly diagnosed multiple myeloma: How many drugs are enough?'. Together they form a unique fingerprint.

Cite this